{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR+Mutations", "query": { "condition": "FGFR Mutations" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR+Mutations&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T02:17:32.709Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02160041", "title": "BGJ398 for Patients With Tumors With FGFR Genetic Alterations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Hematologic Malignancies" ], "interventions": [ { "name": "BGJ398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2014-07-24", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Oceanside, California • San Francisco, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oceanside", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02160041" }, { "nct_id": "NCT06915753", "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Solid Tumors", "Solid Tumor, Adult", "FGFR Gene Amplification", "FGFR Gene Alterations", "FGFR3 Gene Alteration", "FGFR3 Gene Mutation", "Advanced Solid Tumors", "FGFR4 Gene Mutation", "FGFR4 Gene Fusions", "FGF19 Gene Amplification", "FGF19 Gene Overexpression", "FGFR3 Gene Fusions", "Locally Advanced Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "TYRA-430", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-04-24", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915753" }, { "nct_id": "NCT03822117", "title": "Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor Malignancy" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2019-10-17", "completion_date": "2022-03-29", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 44, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03822117" }, { "nct_id": "NCT01831726", "title": "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor Pathway Activations Inhibited by Dovitinib" ], "interventions": [ { "name": "Dovitinib (TKI258)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 80, "start_date": "2013-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Pismo Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831726" }, { "nct_id": "NCT04003610", "title": "Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-05-14", "completion_date": "2021-04-18", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 13, "location_summary": "Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003610" }, { "nct_id": "NCT01752920", "title": "Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Derazantinib low dose range", "type": "DRUG" }, { "name": "Derazantinib middle dose range", "type": "DRUG" }, { "name": "Derazantinib high dose range", "type": "DRUG" }, { "name": "Derazantinib at recommended phase 2 dose (RP2D)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2012-12-10", "completion_date": "2018-08-28", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752920" }, { "nct_id": "NCT07265947", "title": "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Grade Upper Tract Urothelial Carcinoma" ], "interventions": [ { "name": "Dabogratinib (TYRA-300) 60mg", "type": "DRUG" }, { "name": "Dabogratinib (TYRA-300) 80mg", "type": "DRUG" }, { "name": "Dabogratinib (TYRA-300) TBD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2025-12-22", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 7, "location_summary": "Lisle, Illinois • Greenwood, Indiana • Jeffersonville, Indiana + 4 more", "locations": [ { "city": "Lisle", "state": "Illinois" }, { "city": "Greenwood", "state": "Indiana" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Plymouth", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07265947" }, { "nct_id": "NCT04172675", "title": "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Investigator Choice (Gemcitabine)", "type": "DRUG" }, { "name": "Investigator Choice (Mitomycin C)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2020-02-28", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 22, "location_summary": "Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04172675" }, { "nct_id": "NCT05052372", "title": "Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Transitional Cell Carcinoma", "Platinum-Resistant Urothelial Carcinoma", "Bladder Urothelial Carcinoma", "FGFR Mutation", "FGFR2 Gene Mutation", "FGFR3 Gene Mutation", "FGFR2 Amplification", "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Bladder Carcinoma", "Refractory Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Balversa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-11-21", "completion_date": "2022-12-20", "has_results": false, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052372" }, { "nct_id": "NCT05253807", "title": "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 8, "start_date": "2022-04-29", "completion_date": "2023-08-16", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-06-11T02:17:32.709Z", "location_count": 7, "location_summary": "Los Angeles, California • Fort Myers, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253807" } ] }